Prostate Cancer Foundation announces new urine test for prostate cancer available

Unlike PSA test, is ultra specific for prostate cancer

2013-09-27

(Press-News.org) SANTA MONICA, CA -- A new urine test for prostate cancer that measures minute fragments of RNA is now commercially available to men nationwide through the University of Michigan MLabs. The new test—Mi-Prostate Score (MiPS)—improves the utility of the PSA blood test, increases physicians' ability to pick out high-risk prostate tumors from low-risk tumors in patients, and may help tens of thousands of men avoid unnecessary biopsies.

The MiPS test incorporates blood PSA levels and two molecular RNA markers specific for prostate cancer in one final score that provides men and their doctors with a personalized prostate-cancer risk assessment.

Drawbacks of stand-alone PSA testing for prostate cancer

The prostate specific antigen (PSA) is a protein made by the prostate. For decades the PSA test has been used as a marker for the presence of prostate cancer in men—high or rising levels of PSA in blood may indicate the presence of a prostate tumor. However, the PSA test is a non-specific test for prostate cancer. That is, non-cancerous conditions such as an enlarged or inflamed prostate can cause elevations in PSA levels. And even when PSA levels rise above what has routinely been considered a trigger level (4.1 ng/ml in the blood) indicating the need for a needle biopsy to check prostate tissue for signs of cancer, less than half of those biopsies find cancerous cells. In addition, up to 44 percent of PSA-triggered biopsies find cancer cells that are non-lethal, indolent prostate cancer cells. Indolent prostate cancer is highly unlikely to shorten the lifespan of a man. However, treatment with surgery or radiation can carry significant risk of side effects such as incontinence or sexual dysfunction.

Improving upon the PSA test

The limited reliability of the PSA test, and its lack of specificity for prostate cancer, has led to sharp disagreement over the use of the PSA test as a routine health screening measure for men of a certain age. What everyone does agree upon is the need for better markers of prostate cancer. To date there are no perfect biomarkers that identify only high-risk prostate cancer. But each year progress is made toward such a goal. Today, the University of Michigan's Department of Pathology MLabs will begin offering the MiPS urine test that is ultra specific for prostate cancer. The MiPS test scans urine samples for two molecular markers that are distinct to prostate cancer. One marker is a snippet of RNA made from a gene (PCA3) that is overactive in 95 percent of all prostate cancers. The second marker is RNA that is made only when two genes (TMPRSS2 and ERG) abnormally fuse. The presence of this fusion RNA in a man's urine is ultra specific for prostate cancer.

An ultra-specific test for prostate cancer

Dr. Scott Tomlins, MD, PhD, is an assistant professor of pathology and urology at the University of Michigan and a Safeway-Prostate Cancer Foundation Young Investigator. Tomlins co-discovered what is now commonly known as the TMPRSS2:ERG fusion. "The evidence shows that if TMPRSS2:ERG RNA is detectable at high levels in urine, a man likely has prostate cancer, whether or not his biopsy is positive for cancer," said Tomlins. (Because biopsies typically sample less than 1 percent of the prostate gland, cancers can be missed, even high-grade cancers.)

A commercial urine test (PROGENSA PCA3) for PCA3, developed and marketed by the California-based biotech company Gen-Probe, gained FDA approval in 2012 for use in men who are considering repeat biopsy after an initially negative result. While a welcome development, research shows that the new urine test offered by MLabs that measures both PCA3 and TMPRSS2:ERG should improve a doctor's ability to stratify men suspected of having prostate cancer. In a study published in Science Translational Medicine, Tomlins and colleagues found the highest rates of cancer in men with the highest levels of TMPRSS2:ERG and PCA3 in their urine. The men in the study were stratified into three groups based upon the levels of TMPRSS2:ERG and PCA3 in their urine: low, intermediate and high levels, or scores. Cancer was diagnosed in each of the groups respectively: 21%, 43%, and 69%. High-grade prostate cancer, defined in the study as a Gleason score greater than 6, also occurred at different frequencies in the three groups with 7%, 20%, and 40% diagnosed in each group respectively.

Other research has shown that the two-marker urine test is more effective than the PSA test alone, or PSA testing that's incorporated into a commonly used online tool (the Prostate Cancer Risk Calculator), at predicting the presence of prostate cancer.

### For additional research results of the MiPS test, how results will be presented to men and their doctors, and other background information, click here.

From more information on how to send a specimen, please call MLabs at 800-862-7284 or visit http://www.mlabs.umich.edu.

The Prostate Cancer Foundation is not endorsing the use of this test or non-use—PCF does not endorse commercial companies or products. The Foundation heartily applauds each research step made toward precision medicine and better biomarkers for prostate cancer that improves the standard of care for patients and leads to less suffering and death from this disease that will affect one in six men in the US. The Safeway Foundation generously provided unrestricted funding to the Prostate Cancer Foundation for biomarker research that funded this work. The Safeway Foundation also provided PCF-Young Investigator funding to Dr. Tomlins. The Prostate Cancer Foundation is the world's largest philanthropic source of support for accelerating the most promising research for better treatments and cures for prostate cancer. To learn more about PCF go to http://www.pcf.org.

ELSE PRESS RELEASES FROM THIS DATE:

The spliceosome: More than meets the eye

2013-09-27

Certain diseases such as cystic fibrosis and muscular dystrophy are linked to genetic mutations that damage the important biological process of rearranging gene sequences in pre-messenger RNA, a procedure called RNA splicing. These conditions are difficult to prevent because scientists are still grasping to understand how the splicing process works. Now, researchers from Brandeis University and the University of Massachusetts Medical School have teamed up to unravel a major component in understanding the process of RNA splicing. In a recent paper published in Cell ...

In prostate cancer prognosis, telomere length may matter

2013-09-27

Like the plastic caps at the end of shoelaces, telomeres protect — in their case — the interior-gene containing parts of chromosomes that carry a cell's instructional material. Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by Johns Hopkins scientists. "Doctors are looking for new ways to accurately predict prostate cancer patients' prognoses, because the current methods that use disease stage, Gleason score, and PSA ...

Abuse, lack of parental warmth in childhood linked to multiple health risks in adulthood

2013-09-27

The effects of childhood abuse and lack of parental affection can last a lifetime, taking a toll both emotionally and physically. There are many reports assessing the psychological damage resulting from childhood abuse, and the effects on physical health have also been well documented. For instance, this "toxic" stress has been linked to elevated cholesterol, cardiovascular disease, metabolic syndrome and other physical conditions posing a significant health risk. The research into the physical effects of abuse, however, has focused on separate, individual systems. A ...

U.Va. researcher: Methane out, carbon dioxide in?

2013-09-27

A University of Virginia engineering professor has proposed a novel approach for keeping waste carbon dioxide out of the atmosphere. Andres Clarens, an assistant professor of civil and environmental engineering at U.Va.'s School of Engineering and Applied Science, and graduate student Zhiyuan Tao have published a paper in which they estimate the amount of carbon dioxide that could be stored in hydraulically fractured shale deposits after the methane gas has been extracted. Their peer-reviewed finding was published in Environmental Science and Technology, a publication ...

Curiosity's SAM instrument finds water and more in surface sample

2013-09-27

The first scoop of soil analyzed by the analytical suite in the belly of NASA's Curiosity rover reveals that fine materials on the surface of the planet contain several percent water by weight. The results were published today in Science as one article in a five-paper special section on the Curiosity mission. "One of the most exciting results from this very first solid sample ingested by Curiosity is the high percentage of water in the soil," said Laurie Leshin, lead author of one paper and dean of the School Science at Rensselaer Polytechnic Institute. "About 2 percent ...

Several NASA spacecraft track energy through space

2013-09-27

Scientists have provided the most comprehensive details yet of the journey energy from the sun takes as it hurtles around Earth's magnetosphere. Understanding the changes energy from the sun undergoes as it travels away and out into space is crucial for scientists to achieve their goal of some day predicting the onset of space weather that creates effects such as the shimmering lights of the aurora or interruptions in radio communications at Earth. Taking advantage of an unprecedented alignment of eight satellites through the vast magnetic environment that surrounds Earth ...

HS3 mission identifies area of strong winds, rain in Hurricane Ingrid

2013-09-27

One of the instruments that flew aboard one of two unmanned Global Hawk aircraft during NASA's HS3 mission was the Hurricane Imaging Radiometer known as HIRAD. HIRAD identified an area of heavy rains and and likely strong winds in Hurricane Ingrid by measuring surface wind speeds and rain rates using its rectangular antenna to track activity on the ocean's surface. NASA's Global Hawk 871 is the over-storm Global Hawk that carried HIRAD on a flight over Hurricane Ingrid on Sept. 15 as the storm moved through the extreme southwestern Gulf of Mexico and traveled west-northwestward ...

Ballet dancers' brains adapt to stop them getting in a spin

2013-09-27

Scientists have discovered differences in the brain structure of ballet dancers that may help them avoid feeling dizzy when they perform pirouettes. The research suggests that years of training can enable dancers to suppress signals from the balance organs in the inner ear. The findings, published in the journal Cerebral Cortex, could help to improve treatment for patients with chronic dizziness. Around one in four people experience this condition at some time in their lives. Normally, the feeling of dizziness stems from the vestibular organs in the inner ear. These ...

Repurposed antidepressants have potential to treat small-cell lung cancer

2013-09-27

PHILADELPHIA — A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small-cell lung cancer (SCLC), according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research. Based on data generated using bioinformatics, two drugs approved by the U.S. Food and Drug Administration (FDA) to treat symptoms of depression were tested on SCLC cells and animal models. Both antidepressants were found to induce SCLC cell death. They were also effective in mice ...

FDA-approved antidepressant may combat deadly form of lung cancer, Stanford study finds

2013-09-27

STANFORD, Calif. — A little-used class of antidepressants appears potentially effective in combating a particularly deadly form of lung cancer, according to a new study from researchers at the Stanford University School of Medicine. And because the drugs have already been approved by the U.S. Food and Drug Administration for use in humans, the researchers have been able to quickly launch a clinical trial to test their theory in patients. The phase-2 trial is now recruiting participants with small-cell lung cancer and other, similar conditions like aggressive gastrointestinal ...

LAST 30 PRESS RELEASES:

Orthopedic team from Peking Union Medical College Hospital publishes longest-term follow-up study on post-TKA outcomes in Chinese patients with knee osteoarthritis